Tranexamic acid arrived in skincare with an unusual pedigree. Most ingredients start as cosmetic chemistry and later go looking for a study. This one started as a prescription drug, used for decades to reduce bleeding, and someone noticed along the way that it also seemed to quieten a particular kind of brown patch on the face.
That origin is the reason it deserves a careful look, and also the reason most of the excitement around it is slightly misplaced. The strongest numbers in the tranexamic acid literature come from the tablet. The serum on the shelf borrows their reputation.
What it is and why it might work on pigment
Tranexamic acid is a small synthetic molecule that blocks the conversion of plasminogen to plasmin. In medicine that is useful because plasmin breaks down blood clots, and slowing it down reduces bleeding — after surgery, in heavy menstrual bleeding, after dental work.
In skin, plasmin appears to have a second job. It releases signalling molecules that encourage melanocytes, the cells that make pigment, to work harder. Interrupt plasmin and you take one push off the pigment machinery. There is also a vascular component to melasma — the patches tend to sit over skin with more small blood vessels — and tranexamic acid may act there as well.
Notice what this mechanism does not say. It does not say tranexamic acid bleaches anything, and it does not say it breaks up pigment that is already there. It reduces one of the signals that keeps pigment production running. That is a modest, plausible mechanism, and it predicts a modest, slow effect.
What the tablet trials found
The cleanest study is a randomised, placebo-controlled, double-blind trial published by Del Rosario and colleagues in 2018. Forty-four women with moderate to severe melasma took either 250 milligrams of tranexamic acid twice a day or a placebo for three months, with sunscreen in both groups. The melasma severity score fell by 49 percent with tranexamic acid and by 18 percent with placebo.
Two things in that result are worth sitting with. The first is the placebo group: 18 percent improvement from sunscreen and attention alone. Melasma responds to sun avoidance, and any study without a control group will quietly credit that improvement to whatever was being tested. The second is what happened afterwards. In the three months after the tablets stopped, much of the improvement faded. The effect lasts while the drug is being taken.
Oral tranexamic acid is a prescription medicine with real contraindications — it affects clotting, and anyone with a history of thrombosis, certain hormonal medications or a number of other conditions is not a candidate. That decision belongs to a prescriber, not to a skincare routine, and I mention it here only because the tablet results are the ones you will see quoted on serum packaging.
What the topical trials found
Topical tranexamic acid has a respectable number of small trials, and they point in a consistent direction. They are also, almost all of them, comparisons against another treatment rather than against nothing.
Atefi and colleagues in 2017 randomised 60 women with melasma to 5 percent tranexamic acid or 2 percent hydroquinone, applied twice a day for twelve weeks. Both groups improved significantly from baseline, and there was no statistical difference between them. Nobody in the tranexamic acid group reported side effects; in the hydroquinone group, 10 percent reported redness and irritation.
That reads well until you look at the comparator. Two percent hydroquinone is the low end. The usual reference strength in melasma trials is 4 percent. Matching a weaker version of the standard treatment is a real finding, and it is not the same finding as matching the standard.
Ebrahimi and Naeini in 2014 ran a split-face study in 50 women, comparing 3 percent topical tranexamic acid on one side with a hydroquinone-and-dexamethasone combination on the other over twelve weeks. Again both sides improved, again the difference was not significant, and again the tranexamic acid side was better tolerated.
When Kim and colleagues pooled the available studies in a 2017 meta-analysis in Acta Dermato-Venereologica, they found that tranexamic acid — oral, topical and injected — reduced melasma severity scores across the board. What the pooled result cannot fix is what went into it: small trials, short follow-up and methods that differ from study to study. The authors themselves called for larger, longer and better-controlled trials.
Reading the topical numbers honestly
Here is how I would summarise it for a friend. Topical tranexamic acid has a plausible mechanism and a handful of trials, each with somewhere between 20 and 60 people, in which it performed roughly as well as mild versions of the standard treatment and caused less irritation. There is no large placebo-controlled trial of a topical product showing how much of the improvement is the ingredient and how much is the sunscreen everyone in these studies was also using.
That is a real effect, and a modest one, with a ceiling we do not know yet. It is a long way from the way it is sometimes presented, as the gentle answer to every dark mark.
Three practical points follow from it:
- The concentration on the label matters less than the vehicle. Tranexamic acid is water-loving and does not cross the skin barrier easily on its own. The trials used 2 to 5 percent in formulations designed for the purpose. A product listing it near the end of a long ingredient list is not the product that was studied.
- Twelve weeks is the shortest honest test. Every trial worth citing ran for at least that long. A verdict after three weeks says nothing about the ingredient.
- Without daily sun protection the test is meaningless. Every one of these studies required it. In melasma, UV and visible light are the main drivers, and no pigment ingredient outruns them.
Where it fits
Tranexamic acid is a reasonable thing to try for persistent, symmetrical facial pigment if you have sensitive or reactive skin and want something unlikely to irritate. It is not a replacement for the conversation with a qualified prescriber that melasma often needs, and it will not keep working if the sun protection lapses.
It is also a good illustration of a pattern I see often: an ingredient with a genuine medical history, where the medical results get attached to the cosmetic version without the conditions that produced them. The tablet trial is real. The cream is a different product with a smaller, thinner evidence base. Both of those sentences can be true, and the honest label would say so.
The strongest tranexamic acid numbers come from a prescription tablet. The serum has a handful of small trials and a gentle profile — worth trying, measured in months, never without sunscreen.
